Caristo Diagnostics Grows Executive Team with New CCO and CFO Appointments

Caristo Diagnostics Expands Leadership Team

In a strategic move to bolster its operations and accelerate growth within the cardiovascular technology sector, Caristo Diagnostics has announced the addition of two key executives to its leadership team. David Vort has been appointed as Chief Commercial Officer, while Chris Louk steps in as Chief Financial Officer. This expansion comes as Caristo continues to promote the adoption of its AI-driven technologies worldwide, demonstrating the company's commitment to improving cardiovascular health.

Details of the Appointments

Steve Deitsch, the CEO of Caristo Diagnostics, expressed confidence in the new hires, stating that both Vort and Louk possess the skills and experience necessary to guide the company through its next phase of growth. Vort brings to Caristo a wealth of experience, having previously served as the Chief Commercial Officer at Cytovale where he led the commercialization of a key sepsis diagnostic tool. Additionally, he has an impressive track record at iRhythm Technologies, where he was instrumental in scaling revenues significantly.

Louk, on the other hand, comes equipped with vast financial acumen and hands-on experience in strategic planning and capital markets. Before joining Caristo, he held the position of Vice President of Healthcare Investment Banking at Piper Sandler, where he worked on notable transactions, including a substantial equity financing for OrganOx.

Innovation in Cardiac Health

The integration of Vort and Louk into the management team coincides with significant momentum-building at Caristo Diagnostics. The company’s flagship product, CaRi-Plaque, received FDA clearance in 2025 and is now employed in multiple U.S. hospitals and imaging centers. This innovative tool quantifies coronary plaque and stenosis, aiding healthcare professionals in delivering timely interventions to patients at risk of heart attack.

Furthermore, the company also champions its CaRi-Heart product, which utilizes the proprietary Fat Attenuation Index Score (FAI-Score™) to measure levels of coronary inflammation. Currently available in the UK, Europe, Switzerland, and Australia, this product is making strides in enhancing early diagnosis capabilities in cardiovascular care.

Commitment to Health and Growth

Caristo Diagnostics, which originated as a spinout from the prestigious University of Oxford, is dedicated to employing advanced technologies to detect cardiovascular disease in its early stages, ultimately saving lives through timely interventions. The enhancements in leadership are poised to foster further innovations and facilitate greater outreach to clinicians and patients alike.

Recognized as a '2026 Technology Pioneer' by the World Economic Forum, Caristo highlights its ambition not only in the commercial realm but also in contributing to the global fight against heart disease through groundbreaking research and technologies. With these leadership changes, the company is well-prepared to forge ahead in its mission to revolutionize cardiovascular healthcare.

Looking Ahead

As Caristo Diagnostics prepares to further its reach and impact, the industry stakeholders and healthcare providers eagerly await the advancements that will unfold under the guidance of its newly appointed executives. The cardiovascular technology landscape is ever-evolving, and with Vort and Louk at the helm, Caristo is set to make substantial contributions to both the commercial and healthcare sectors in the years to come.